The present invention relates to a biodegradable plastic made from a combination of at least one synthetic plastic polymer, at least one natural polymer and a natural polymer attacking agent and articles made therefrom. The present invention further relates to a method of eliminating hydrocarbon contaminating a region subjected to extreme temperatures by contacting the region with hydrocarbon-degrading microorganisms and adjusting the temperature of the region for optimum growth. The present inv...

A constant order release aspirin tablet comprising aspirin, from 0.5 to 10 weight percent of a hydrogenated vegetable oil and from 0.5 to 7 weight percent of a saccharide selected from the group consisting of lactose, sucrose, dextrose fructose and maltose. The aspirin tablet is administered once or twice a day for the chronic treatment of arthritis, and has substantially lessened gastrointestinal side effects.

Ibuprofen-aspirin compounds useful in treating aspirin or ibuprofen-treatable conditions, hydroxymethylacylfulvene analogs useful as antitumor drugs, and L-sugar illudin analogs useful as antitumor drugs.

Kits are provided that can be used to determine a thromboxane B.sub.2 metabolite level and a creatinine level in a biological sample, particularly a human urine sample. This information can be used to optimize aspirin dosage in a patient. The present invention further includes calibrant preparations. In some embodiments, these calibrants comprise urine, particularly human urine that is identified in repeated trials to provide a consistent and reproduceable level of thromboxane B.sub.2 metabolite...

The method of providing cytoprotection of the gastric mucosa in a mammal receiving aspirin (ASA) perorally which comprises orally administering either prior to or in combination with ASA a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid] (TBPA) or in combination with a pharmaceutically acceptable carrier. Also shown is a composition for providing cytoprotection of the gastric mucosa in a mammal receiving ASA perorally which comprises ASA in combination with a cytoprotectively ef...

The invention provides the use of a cycloaygenase inhibitor such as the non-steroidal anti-inflammatory agent aspirin in the manufacture of a medicament to enhance perfusion of blood through the mammalian, preferably human, uterus. The enhanced perfusion aids implantation in natural or assisted methods of conception

A compressed and formed alkaline component suitable for use in a buffered aspirin product. The alkaline component is made of alkaline materials selected from the group consisting of calcium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide and mixtures thereof and having incorporated therein citric acid and monobasic sodium phosphate.

Aspirin compositions for oral and topical use are stabilized by reaction with potassium hydroxide.

A chewable aspirin and buffering material tablet and method for producing same is disclosed herein. In a single dosage form the aspirin and buffering materials are integrally dispersed and bound in a fatty material of chocolate, synthetic chocolate or hydrogenated tallow. The tablet is for gastrointestinal applications and is especially adopted for use with animals, particularly dogs, and can be molded into a variety of shapes including that of a miniature dog bone.

The invention relates to a novel method of administering aspirin to achieve improved delivery thereof. The invention further relates to novel dosage forms of neutralized aspirin adapted for nasal administration, such as solutions, suspensions, gels and ointments. These dosage forms find utility in the treatment of conditions known to respond to the administration of aspirin, particularly in the treatment of migraine and in the mitigation of cardiovascular damage resulting from heart attack.